Data gathered: January 2
AI Stock Analysis - Agenus (AGEN)
Analysis generated June 30, 2024. Powered by Chat GPT.
Agenus is a biopharmaceutical company focused on the development and commercialization of immuno-oncology treatments. They leverage their extensive research and development capabilities to create innovative therapies targeting various forms of cancer. The company is striving to make significant breakthroughs in the sector by harnessing the body's immune system to fight cancer more effectively.
Stock Alerts - Agenus (AGEN)
 |
Agenus | January 2 Price is up by 5.1% in the last 24h. |
|
Agenus | December 27 Price is down by -5.3% in the last 24h. |
|
Agenus | December 20 Price is up by 5.1% in the last 24h. |
|
Agenus | December 18 Price is down by -5.6% in the last 24h. |
Alternative Data for Agenus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 62 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | 6 | Sign up | Sign up | Sign up |
| Patents | 89 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,564 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,695 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 22 | Sign up | Sign up | Sign up |
| Linkedin Employees | 290 | Sign up | Sign up | Sign up |
About Agenus
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer.
| Price | $2.98 |
| Target Price | Sign up |
| Volume | 30,540 |
| Market Cap | $65M |
| Year Range | $2.57 - $17.73 |
| Dividend Yield | 0% |
| PE Ratio | 0.46 |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
 |
Agenus Inc. (NASDAQ:AGEN) Short Interest UpdateDecember 31 - ETF Daily News |
|
Wellington Management Group LLP Sells 6,232 Shares of Agenus Inc. (NASDAQ:AGEN)December 21 - ETF Daily News |
|
Agenus Inc. (NASDAQ:AGEN) Shares Acquired by Fmr LLCDecember 19 - ETF Daily News |
 |
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersDecember 18 - Investing.com |
|
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from AnalystsDecember 15 - ETF Daily News |
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With AgenusDecember 12 - Financial Post |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 25M | 150,000 | 25M | -66M | -28M | 0.000 |
| Q2 '24 | 24M | 120,000 | 23M | -53M | -27M | -2.520 |
| Q1 '24 | 28M | 110,000 | 28M | -62M | -30M | -3.040 |
| Q4 '23 | 84M | 260,000 | 83M | -46M | 1M | -0.130 |
| Q3 '23 | 24M | 300,000 | 24M | -62M | -43M | -0.160 |
Insider Transactions View All
| ARMEN GARO H filed to buy 625,969 shares at $0.6. February 15 '24 |
| WIINBERG ULF filed to buy 124,063 shares at $0.8. November 17 '23 |
| O'Day Steven J filed to sell 61,321 shares at $3.1. January 6 '22 |
Similar companies
Read more about Agenus (AGEN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Agenus?
The Market Cap of Agenus is $65M.
What is Agenus' PE Ratio?
As of today, Agenus' PE (Price to Earnings) ratio is 0.46.
What is the current stock price of Agenus?
Currently, the price of one share of Agenus stock is $2.98.
How can I analyze the AGEN stock price chart for investment decisions?
The AGEN stock price chart above provides a comprehensive visual representation of Agenus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Agenus shares. Our platform offers an up-to-date AGEN stock price chart, along with technical data analysis and alternative data insights.
Does AGEN offer dividends to its shareholders?
As of our latest update, Agenus (AGEN) does not offer dividends to its shareholders. Investors interested in Agenus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Agenus?
Some of the similar stocks of Agenus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.